/
Other
Necrosis
19
Pipeline Programs↗
16
Active Trials↗
13
Companies Involved↗
Necrosis is an emerging landscape with 19 programs across 13 companies. The most active players are Qilu Pharmaceutical Co., Ltd.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 1
No programs
Phase 23
Phase 34
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
16 of 19 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.
Analysis
Trial Status
66
clinical trials
Completed32 · 48%
Terminated10 · 15%
Recruiting7 · 11%
Unknown status7 · 11%
Not yet recruiting6 · 9%
Active, not recruiting3 · 5%
Other1 · 2%
Clinical Trials
Trial Activity
66 trials
Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
Not yet recruiting·—·Phase 2/3·NCT07161843·500 enrolled
Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout
Not yet recruiting·—·N/A·NCT05925166·100 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)